NasdaqGS - Nasdaq Real Time Price USD
Replimune Group, Inc. (REPL)
7.85
+0.62
+(8.58%)
At close: May 16 at 4:00:00 PM EDT
7.84
-0.01
(-0.13%)
After hours: May 16 at 7:38:09 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 5 | 3 |
| Avg. Estimate | -0.69 | -0.63 | -2.81 | -2.39 |
| Low Estimate | -0.74 | -0.63 | -2.99 | -2.48 |
| High Estimate | -0.64 | -0.63 | -2.65 | -2.22 |
| Year Ago EPS | -0.25 | -0.78 | -3.24 | -2.81 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 6 | 4 |
| Avg. Estimate | -- | -- | 2.01M | 46.33M |
| Low Estimate | -- | -- | -- | 2.4M |
| High Estimate | -- | -- | 12.05M | 100.33M |
| Year Ago Sales | -- | -- | -- | 2.01M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 2,206.11% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.8 | -0.83 | -0.74 | -0.72 |
| EPS Actual | -0.25 | -0.78 | -0.68 | -0.79 |
| Difference | 0.55 | 0.05 | 0.06 | -0.07 |
| Surprise % | 68.62% | 6.59% | 7.69% | -9.72% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.69 | -0.63 | -2.81 | -2.39 |
| 7 Days Ago | -0.7 | 0 | -2.83 | -2.26 |
| 30 Days Ago | -0.7 | 0 | -2.66 | -2.14 |
| 60 Days Ago | -0.76 | 0 | -2.63 | -2.1 |
| 90 Days Ago | -0.76 | 0 | -2.64 | -2.23 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | 1 | -- | -- | 1 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | -- | 4 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| REPL | -176.00% | 19.23% | 13.19% | 15.15% |
| S&P 500 | 13.21% | 2.76% | 7.83% | 13.78% |
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 2/26/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/13/2025 |
| Maintains | BMO Capital: Outperform to Outperform | 1/22/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/22/2025 |
| Maintains | Jefferies: Buy to Buy | 12/4/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 11/22/2024 |
Related Tickers
CGEM Cullinan Therapeutics, Inc.
7.50
+3.59%
KURA Kura Oncology, Inc.
6.02
+1.18%
STOK Stoke Therapeutics, Inc.
9.76
+1.35%
SRRK Scholar Rock Holding Corporation
30.55
-0.91%
JANX Janux Therapeutics, Inc.
24.28
+4.34%
YMAB Y-mAbs Therapeutics, Inc.
4.1000
+6.22%
ETNB 89bio, Inc.
7.78
+1.77%
ORIC ORIC Pharmaceuticals, Inc.
4.7300
-0.21%
SNDX Syndax Pharmaceuticals, Inc.
9.05
+1.12%
URGN UroGen Pharma Ltd.
7.31
-25.79%